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Abstract
Background: The objective of this study was to study how changing the ratio of Lys to Thr, Lys to His, and Lys to
Val affects the expression of lipogenic genes and microRNA (miRNA) in bovine mammary epithelial cells.
Results: Triplicate cultures with the respective “optimal” amino acid (AA) ratio (OPAA = Lys:Met 2.9:1; Thr:Phe 1.05:1;
Lys:Thr 1.8:1; Lys:His 2.38:1; Lys:Val 1.23:1) plus rapamycin (OPAARMC; positive control), OPAA, Lys:Thr 2.1:1 (LT2.1),
Lys:Thr 1.3:1 (LT1.3), Lys:His 3.05:1 (LH3.0), or Lys:Val 1.62:1 (LV1.6) were incubated in lactogenic medium for 12 h.
The expression of 15 lipogenic genes and 7 miRNA were evaluated. Responses to LT2.1, LT1.3, LH3.0, and LV1.6
relative to the control (OPAARMC) included up-regulated expression of ACSS2, FABP3, ACACA, FASN, SCD, LPIN1,
INSIG1, SREBF1, PPARD, and NR1H3 (commonly known as LXR-α). Furthermore, LV1.6 up-regulated expression of
ACSL1, DGAT1, and RXRA and down-regulated PPARG expression. Although no effect of OPAA on expression of
PPARG was observed, compared with the control, OPAA up-regulated expression of the PPAR targets ACSS2, FABP3,
ACACA, FASN, SCD, LPIN1, INSIG1, and SREBF1. Compared with the control, the expression of the anti-lipogenic
MIR27AB was down-regulated by OPAA, LT2.1, LT1.3 and LH3.0. In contrast, compared with the control, the
expression of the pro-lipogenic MIR21 was up-regulated by LT2.1, LT1.3, LH3.0, and LV1.6.
Conclusions: The observed up-regulation of lipogenic gene networks and the changes in expression of key miRNA
involved in the control of lipogenic balance are indicative of a potentially important role of EAA ratios and mTOR
signaling in the regulation of milk fat synthesis.
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Background
Previous research has underscored that provision of
adequate levels of essential AA (EAA) is critical for
improving N utilization efficiency as well as maximiz-
ing bovine milk protein synthesis [1]. Rulquin et al. [2]
proposed “ideal” values for intestinal absorption of
EAA in dairy cows; however, after absorption, AA flow
first to the liver where substantial and differential net
removal occurs leading to marked alterations in the
pattern of AA that can be supplied to the mammary
gland [3]. Hence, studies evaluating the effects of EAA
in mammary cells are essential to improve our under-
standing of their metabolism and the underlying
mechanisms [4–7]. Such experiments have been in-
strumental in efforts to improve the efficiency of diet-
ary protein use in dairy cows by allowing the
development of mechanistic models that can help
guide the design of future experiments [8].
Both Lys and Met, at supraphysiological concentra-
tions, are known to stimulate β-casein synthesis in
dairy cow mammary epithelial cells (MEC) [5, 6]. It
was demonstrated in murine MEC that Lys, His, and
Thr when added to an AA-depleted medium, exerted
* Correspondence: liujx@zju.edu.cn; jloor@illinois.edu
1Institute of Dairy Science, College of Animal Sciences, Zhejiang University,
Yuhangtang Road 866, Hangzhou 310058, People’s Republic of China
2Department of Animal Sciences, Mammalian NutriPhysioGenomics,
University of Illinois, 1207 West Gregory Drive, Urbana, IL 61801, USA
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Li et al. Journal of Animal Science and Biotechnology  (2016) 7:44 
DOI 10.1186/s40104-016-0104-x
negative effects on S6K1 and 4E-BP1 phosphorylation
via the specific AA pathway that signals to mTOR
complex 1 (mTORC1) [9]. Subsequent studies using
bovine MEC have explored the effects of individual
EAA on milk protein mRNA expression, cell signaling
and milk protein synthesis [5–7]. However, an unex-
plored area of EAA metabolism within bovine MEC is
the potential effect of these nutrients on gene expres-
sion of lipogenic target genes. The fact that mTORC1
is required for Akt-mediated induction of SREBP-1c in
retinal pigment epithelial cells [10] indicates a poten-
tial link between AA and lipogenesis. Indeed, a puta-
tive role for AA on lipogenesis has been uncovered
using non-ruminant hepatocytes where Met and Lys
plus insulin not only altered mTOR signaling but also
the expression of fatty acid (FA) synthase (FASN) [11].
Furthermore, Leu and Gln increased activity of acetyl-
CoA carboxylase (ACACA) [12] in rat hepatocytes.
A “missing link” between EAA availability and alter-
ations in lipogenic gene expression in the studies re-
ported to date could be alterations in peroxisome
proliferator-activated receptor-γ (PPARG) and/or
sterol-responsive element binding factor 1 (SREBF1)
expression and/or signaling. Both of these transcrip-
tion regulators are up-regulated (along with their tar-
get genes) in bovine mammary gland at the onset and
throughout lactation [13]. Evidence for the control of
PPARG via microRNA (miRNA) was reported recently
in studies where up-regulation of MIR27AB led to
downregulation of PPARG expression and lipogenesis
in adipocytes [14]. Hence, this miRNA and others
such as MIR34A, MIR130A, and MIR448 [15] have
the potential to control mammary lipogenesis through
negative effects on PPARG. In the context of control-
ling the cellular lipogenic balance, it is noteworthy
that PPARG itself alters transcription of MIR103 and
MIR378, hence, these miRNA could elicit a pro-
lipogenic effect through targets such as FASN [16].
Recent work also provides evidence for a positive co-
operative mechanism between MIR21 and SREBF1 in
the control of lipogenesis [17].
The general hypothesis was that the EAA profile
could affect mRNA expression of lipogenic gene net-
works and selected lipogenic miRNA in bovine
mammary cells. Because of the newly-demonstrated
linkage between mTOR signaling and activation of
lipogenesis via the Liver-X-receptor α (gene symbol
NR1H3) and SREBF1 [15], it was important to deter-
mine gene transcription relative to the inhibition of
mTOR signaling using Rapamycin. Therefore, the
specific objective was to culture MEC with specific
EAA ratios and profile the mRNA expression of
several lipogenic genes as well as lipogenic/anti-lipogenic
miRNA.
Methods
Cell culture and treatments
Bovine mammary epithelial cells (Mac-T) were allowed to
grow in canted neck, vented, 75 cm2 flasks (430641,
Corning, Glendale, AZ) in Minimum Essential Medium/
Earle’s Balanced Salts HyQ (MEM/EBSS, HyClone, Logan,
UT). Cultures were maintained in a water-jacketed incu-
bator (model 3158, Forma Scientific, Marietta, OH) with
5 % in air at 37 °C. Culture medium was changed every
24 h and cells were subcultured to 80 to 90 % confluence
by rinsing once with (10 mL) of PBS buffer without Ca
and Mg (sh3002802, HyClone), 3 mL of 0.25 % trypsin
(sh3004201, HyClone) plus 3 mL of Cellstripper (25-056-
Cl, Cellgro, Herndon, VA), and incubated at 37 °C for 5 to
10 min (i.e., until evidence of cell detachment). Trypsin
activity was inhibited by addition of 6 mL of fresh culture
media at 37 °C.
Approximately 48 h prior to the last subculture before
initializing the experiment, cells were allowed to grow in
a basal medium composed of Minimum Essential
Medium/Earle’s Balanced Salts HyQ (MEM/EBSS,
HyClone), insulin (5 mg/L, NC0374447, Fisher Scientific,
Pittsburgh, PA), hydrocortisone (1 mg/L, H0888, Sigma,
St. Louis, MO), transferrin (5 mg/L, T1428, Sigma), as-
corbic acid (5 μmol/L, A4544, Sigma), sodium acetate (5
mmol/L, S5636, Sigma), and penicillin/streptomycin
(10 mL/L, P4333, Sigma). The basal medium was sup-
plemented with fetal bovine serum (10 %, FBS,
SH3007002, HyClone) and growth-promoting hormones
(1 mg/L of progesterone, P8783, Sigma; 0.05 % lactalbu-
min, L5385, Sigma; and 0.05 % α-lactose, 47287-U,
Sigma). When the cells reached ~90 % confluence they
were cultured overnight with 2.5 mL of a lactogenic
medium in 6-well plates as reported by Kadegowda et al.
[18]. The lactogenic medium was prepared as the basal
medium, except that essential AA-free high-glucose
Dulbecco’s modified Eagle’s medium (HG-DMEM,
Gibco Custom Media, Invitrogen) was used. The AA
composition of the basal medium is reported in Table 1.
The lactogenic medium was devoid of fetal bovine
serum and was supplemented with BSA (1 g/L), prolac-
tin (2.5 mg/L) and EAA to achieve the different AA
treatment ratios using the required amount of each indi-
vidual EAA (L-isomer; Sigma-Aldrich) to the lactogenic
medium.
Triplicate cultures were incubated for 12 h with the
following treatments (Table 1): “optimal” AA ratio
(OPAA = Lys:Met 2.9:1; Thr:Phe 1.05:1; Lys:Thr 1.8:1;
Lys:His 2.38:1; Lys:Val 1.23:1), OPAA plus Rapamycin
(OPAARMC, control), Lys:Thr 2.1:1 (LT2.1), Lys:Thr
1.3:1 (LT1.3), Lys:His 3.05:1 (LH3.0), and Lys:Val 1.62:1
(LV1.6). The OPAA was designed to resemble the pro-
files proposed by Rulquin et al. [2]; the other treatments
were designed to change the specific ratio described in
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the treatments by keeping Lys constant and altering the
concentration of the other AA, while also keeping the
other AA constant as in the OPAA. Compared with
OPAA, LT1.3 was 39 % greater in Thr and Phe, LT2.1
was 14 % lower in Thr and Phe, LH3.0 was 23 % lower
in His, and LV1.6 was 24 % lower in Val. The concentra-
tions of AA in the experimental media were approxi-
mately 8 times the normal physiological concentrations
in plasma, ranging across EAA from 4 to 20 times the
normal concentration. The decision to increase the ratio
of Lys to His was based on the observation that removal
of rumen-protected His in a diet predicted to be limiting
in MP resulted in lower milk protein and fat yields com-
pared with a diet containing rumen-protected Lys, Met,
and His [19]. In that study, addition of His increased
milk fat yield by 30 g/d compared with the MP-deficient
diet. Despite the lack of effect on milk fat yield, the
higher ratio of Lys to Val used in the present study was
to mimic the lowest level of Val recommended in the
literature [20]. Similarly, the chosen ratio of Thr to Phe
was to maintain it as close as possible to the theoretical
optimal (~1.0:1.0) as discussed in Haque et al. [1]. The
Lys to Thr ratios were chosen based on data from
Prizant and Barash [9].
Preliminary time-course study
The Mac-T cells from several 75 cm2 flasks were
pooled after trypsinization in a 50-mL tube and mixed
thoroughly before transferring to 6-well plates for
addition of treatments. As reported above, cultures
were maintained for 24 h in a lactogenic medium be-
fore treatments were applied (~90 % confluence). For
RNA extraction, cells were cultured in duplicate to
generate three specific treatments: an essential AA-
free treatment (−EAA, HG-DMEM without EAA),
OPAARMC and OPAA. These treatments were per-
formed for 0, 1, 6, 12 h. Cells were harvested in 1 mL
Table 1 Amino acid composition of experimental treatments
Treatmentsa
OPAARMC OPAA LT1.3 LT2.1 LH3.0 LV1.6
Experiment, μg/mL
Lys 175 175 175 175 175 175
Met 60 60 60 60 60 60
Lys/Met 2.9:1 2.9:1 2.9:1 2.9:1 2.9:1 2.9:1
Thr 97 97 135 83 97 97
Phe 92 92 128 79 92 92
Thr/Phe 1.05:1 1.05:1 1.05:1 1.05:1 1.05:1 1.05:1
Lys/Thr 1.8:1 1.8:1 1.3:1 2.1:1 1.8:1 1.8:1
His 74 74 74 74 57 74
Lys/His 2.38:1 2.38:1 2.38:1 2.38:1 3.05:1b 2.38:1
Val 142 142 142 142 142 108
Lys/Val 1.23:1 1.23:1 1.23:1 1.23:1 1.23:1 1.62:1c
Rapamycin, ng/mL 9.147 - - - - -
Other amino acids, μg/mL
Arg 84 84 84 84 84 84
Cys 63 63 63 63 63 63
Gln 584 584 584 584 584 584
Gly 30 30 30 30 30 30
Ile 105 105 105 105 105 105
Leu 105 105 105 105 105 105
Ser 42 42 42 42 42 42
Trp 16 16 16 16 16 16
Tyr 104 104 104 104 104 104
aOPAARMC = optimal amino acid ratios with rapamycin (control); OPAA = optimal amino acid; LT2.1 = Lys:Thr at 2.1; LT1.3 = Lys:Thr at 1.3; LH3.0 = Lys:His at 3.05;
LV1.6 = Lys:Val at 1.62. Amino acid ratios derived from Rulquin et al. [2]. Experimental treatments were designed by adding the required amount of the essential
AA to the basal lactogenic essential AA-free media (HG-DMEM, Custom Media, Invitrogen) to reach the desired concentration
bFrom Lee et al. [19]
cFrom Haque et al. [22]
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of QIAzol reagent (Invitrogen) and stored at −80 °C
until RNA extraction.
The preliminary study was conducted to determine a
suitable incubation time based on peak mRNA expres-
sion of the genes eukaryotic translation initiation factor
4E, eukaryotic translation initiation factor 4E-binding
protein 1, mechanistic target of rapamycin (Ser/Thr kin-
ase), ras homolog enriched in brain, ribosomal protein
S6 kinase beta-1, and tuberous sclerosis 1 (data not
shown). The final data for statistical analysis were calcu-
lated as the percentage change relative to time 0 for all
treatments. Statistical analysis was performed using the
MIXED procedure of SAS (version 9.1, SAS Institute,
Cary, NC) to evaluate the effects of treatment, time, and
treatment × time on normalized mRNA expression of
genes. The model included the fixed effect of time (0, 1,
6, and 12 h), treatment (−EAA, OPAARMC, and
OPAA), and the random effect of replicate nested within
treatment and time. Results (not shown) indicated that a
12-h incubation was suitable to obtain maximal re-
sponses in mRNA expression. Clearly, this represented a
compromise because it is unlikely that all genes would
have maximal expression at the same time point.
Main experiment
To obtain a large number of cells to initiate the main ex-
periment, several subcultures were performed. When the
numbers of cells were deemed adequate to initiate the
experiment, all the cells were pooled in a 50-mL sterile
tube with fresh medium at 37 °C and mixed thoroughly
before plating in 75 cm2 flasks with lactogenic medium.
In doing this we attempted to obtain the same initial
number of cells in each flask and, thus, ensure
consistency for the initial conditions among all samples.
Before initiating the experiment, cells remained in the
basal medium (changed every 24 h) for approximately 2
d, when they reached ≥ 90 % confluence. Subsequently,
cells were cultured in lactogenic medium overnight be-
fore the treatments were applied. The OPAA,
OPAARMC, LT2.1, LT1.3, LH3.0, and LV1.6 treatments
in lactogenic medium (as described above in the “cell
culture and treatments” section were incubated in tripli-
cate (i.e., 3 separate flasks per treatment) before the cells
were harvested after 12 h of incubation.
RNA extraction and quantification
Total RNA was extracted from the cells using the
RNeasy Mini Kit columns (Qiagen, Valencia, CA). Con-
centrations of RNA were measured with a NanoDrop
ND-1000 spectrophotometer (NanoDrop Technologies,
Wilmington, DE). RNA integrity (RIN) was assessed
using Aglient 2100 Bioanalyzer (Aglient Technologies,
Senta Clara, CA). The RIN factor was above 7.5. A por-
tion of the RNA was diluted to 100 ng/μL using RNase
free water before reverse transcriptase. Adequate cDNA
was prepared to run all selected genes. Each cDNA was
synthesized using 100 ng RNA, 1 μL Random Primers
(Roche, Basel, Switzerland), and 9 μL RNase free water.
The mixture was incubated at 65 °C for 5 min in an
Eppendorf Mastercycler Gradient and keep on ice for
3 min. A total of 9 μL of Master Mix, composed of 4 μL
5 × First-Strand Buffer (Fermentas, Pittsburgh), 1 μL
Oligo dT18, 2 μL 10 mmol/L deoxynucleotide 5′-tri-
phosphate mix (Invitrogen), 0.25 μL Reverse aid RT
(Fermentas), 0.125 μL RNase Inhibitor (Fermentas), and
1.625 μL RNase free water was added. The reaction was
performed using the following temperature program:
25 °C for 5 min, 42 °C for 60 min, and 70 °C for 5 min.
Complementary DNA was then diluted 1:4 with RNase
free water.
The qPCR was performed in a MicroAmp Optical
384-well reaction plate (Applied Biosystems, Foster City,
CA) using 4 μL diluted cDNA combined with 6 μL of a
mixture composed by 5 μL 1 × SYBR Green Master Mix
(Quanta, Gaithersburg, MD), 0.4 μL each of 10 μmol/L
forward and reverse primers, and 0.2 μL RNase free
water. Each sample was run in triplicate and a 6-point
relative standard curve plus the nontemplate control
were used. The reactions were performed in an ABI
Prism 7900 HT SDS instrument (Applied Biosystems)
under the following conditions: 5 min at 95 °C, 40 cycles
of 1 s at 95 °C, and 30 s at 60 °C. The presence of a sin-
gle PCR product was verified by the dissociation proto-
col using incremental temperatures to 95 °C for 15 s,
65 °C for 15 s, and 95 °C for 15 s. Data were analyzed
using with the 7900 HT Sequence Detection Systems
Software (version 2.4, Applied Biosystems). Methods for
primer design and validation were reported previously
[18]. Additional details on selected genes and real-time
PCR performance for each gene analyzed are reported in
Additional file 1: Table S1.
Calculation and statistical analysis
The relative percentage of mRNA abundance among
genes was analyzed as reported previously [13]. The qPCR
data were normalized using the geometric mean of the
three internal control genes (GADPH, UXT, and RPS9)
[21]. The MIXED procedure of SAS (version 9.1, SAS
Institute, Cary, NC) was used to evaluate the treatment ef-
fects on mRNA expression (fold-change) relative to the
control (OPAARMC). Fixed effects in the model were
treatments, whereas the random effect was replicate
nested within treatment (n = 3 cultures/treatment). The
Kenward-Roger statement was used for computing the de-
nominator degrees of freedom. Treatment means were
compared using the PDIFF statement in SAS after correc-
tion using Tukey’s. Significance was declared at a PDIFF
Tukey-adjusted P < 0.05.
Li et al. Journal of Animal Science and Biotechnology  (2016) 7:44 Page 4 of 11
Results
Genes associated with FA metabolism
The responses of genes associated to FA metabolism are
reported in Fig. 1. The mRNA expression of acyl-CoA
synthetase long-chain family member 1 (ACSL1) was
greatest with LV1.6 (P < 0.01) compared with other treat-
ments. Compared with the control (OPAARMC), the ex-
pression of acyl-CoA synthetase short-chain family
member 2 (ACSS2) and fatty acid-binding protein 3,
muscle and heart (FABP3) was greater with OPAA,
LT2.1, LT1.3, LH3.0 and LV1.6. Incubation with LT1.3
up-regulated the expression of ACSS2 compared with
LH3.0 (P < 0.01) and LV1.6 (P < 0.01), while LV1.6 down-
regulated ACSS2 compared with LH3.0 (P < 0.01). Treat-
ment with OPAA led to greater expression of FABP3
compared with LH3.0 (P = 0.04) and LV1.6 (P < 0.01),
while incubation with LV1.6 resulted in lower expression
compared with LT2.1 (P < 0.01) and LT1.3 (P < 0.01).
Among the genes associated with de novo FA synthe-
sis and desaturation, acetyl-coenzyme A carboxylase
alpha (ACACA), fatty acid synthase (FASN) and stearoyl-
CoA desaturase (SCD) had greater expression in
response to OPAA, LT2.1, LT1.3, LH3.0 and LV1.6 com-
pared with the control. The LH3.0 resulted in lower ex-
pression of FASN compared with the other treatments
(P < 0.01), while the expression of SCD was up-regulated
in OPAA compared with LH3.0 (P < 0.01).
Expression of 1-acylglycerol-3-phosphate O-acyltransferase
6 (AGPAT6) was up-regulated with LT1.3 (P < 0.01)
and LH3.0 (P < 0.01) compared with the control. The
mRNA expression of diacylglycerol acyltransferase 1
(DGAT1) was down-regulated with OPAA compared
with the control (P < 0.01), but was upregulated by
LV1.6 compared with the other treatments (P = 0.01).
The mRNA abundance of lipin 1 (LPIN1) was greater
(P = 0.04) with OPAA, LT2.1, LT1.3, LH3.0 and LV1.6
compared with the control, while LH3.0 had greater
(P < 0.01) expression compared with OPAA and LV1.6.
Genes associated with regulation of transcription
The responses of genes associated with regulation of
transcription are reported in Fig. 1. The expression of
insulin induced gene 1 (INSIG1) and sterol regulatory
element-binding transcription factor 1 (SREBF1) was
up-regulated (P < 0.05) with OPAA, LT2.1, LT1.3,
LH3.0 and LV1.6 compared with the control. Further-
more, incubation with LT1.3 up-regulated the expres-
sion of INSIG1 compared with LH3.0 (P = 0.02) and
LV1.6 (P < 0.01), while LV1.6 resulted in lower expres-
sion compared with LH3.0 (P < 0.01). For SREBF1,
treatment with LV1.6 resulted in greater expression
compared with the other treatments (P < 0.01). The
mRNA expression of peroxisome proliferator-activated
receptor gamma (PPARG) was lowest with LV1.6
FA activation and Intra-cellular transport
Triacylglycerol synthesis













































































































































































Fig. 1 Expression of genes involved in fatty acid (FA) activation and
intracellular FA transport, de novo FA synthesis and FA desaturation,
triacylglycerol synthesis, and regulation of transcription. Superscript
letters denote significant differences among treatments (P < 0.05).
OPAARMC= optimal amino acid with rapamycin (control); OPAA =
optimal amino acid; LT2.1 = Lys:Thr at 2.1; LT1.3 = Lys:Thr at 1.3; LH3.0 =
Lys:His at 3.05; LV1.6 = Lys:Val at 1.62. ACSS2= acyl-CoA synthetase
short-chain family member 2; ACSL1= acyl-CoA synthetase long-chain
family member 1; FABP3 = FA-binding protein, heart; ACACA =
acetyl-coenzyme A carboxylase alpha; FASN = FA synthase; SCD =
stearoyl-CoA desaturase; AGPAT6 = 1-acylglycerol-3-phosphate
O-acyltransferase 6; DGAT1 = diacylglycerol acyltransferase 1;
LPIN1= lipin 1; INSIG1= insulin induced gene 1; SREBF1= sterol regulatory
element-binding transcription factor 1; PPARG= peroxisome proliferator-
activated receptor gamma; PPARD= peroxisome proliferator-activated
receptor beta; NR1H3= liver X receptor α; and RXRA= retinoid X
receptor alpha
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compared with other treatments (P < 0.01). Compared
with the control, expression of peroxisome proliferator-
activated receptor beta (PPARD) was up-regulated with
OPAA, LT2.1, LT1.3, LH3.0 and LV1.6 (P < 0.01). In
contrast, OPAA resulted in lower expression of LT2.1,
LT1.3, LH3.0 and LV1.6 (P < 0.01). The expression of ret-
inoid X receptor alpha (RXRA) was down-regulated with
OPAA (P = 0.01) and up-regulated with LV1.6 (P < 0.01)
compared with the control. The expression of liver X re-
ceptor α (NR1H3) was up-regulated (P < 0.01) with LT2.1,
LT1.3, LH3.0 and LV1.6 compared with the control, while
LV1.6 resulted in greater (P < 0.01) expression than LT2.1,
LT1.3 and LH3.0.
MicroRNA expression
MicroRNA expression responses to treatments are re-
ported in Fig. 2. Unlike the lipogenic target genes, only 2
of the 7 miRNA evaluated were affected by the treat-
ments (Fig. 2). Compared with OPAA and the control,
the expression of MIR21 was greater (P < 0.01) in re-
sponse to LT2.1, LT1.3, LH3.0 and LV1.6. Treatment
with LV1.6 resulted in lower (P < 0.01) expression of
MIR21 compared with LT2.1, LT1.3 and LH3.0. Com-
pared with the control, the expression of MIR27AB was
lower (P < 0.01) in response to OPAA, LT2.1, LT1.3 and
LH3.0, while LV1.6 led to similar expression than the
control.
Discussion
Indirect regulation of mammary lipogenic gene networks
via the mTOR pathway
Signaling through mTOR plays a crucial role in mam-
mary protein synthesis, and some amino acids, e.g. Leu,
Ile and Val, are known to be potent stimulators of
mTOR signaling and protein synthesis in mouse and bo-
vine [5–7]. Other EAA such as Lys, His and Thr inhib-
ited the mTOR pathway in mammary cells when added
at supraphysiological concentrations to AA-depleted cell
culture medium [9]. The fact that some EAA are potent
activators of the mTOR signaling pathway and alter lipo-
genic gene transcription in non-ruminants [11, 12] led
us to infer that a similar mechanism could exist in bo-
vine mammary cells. In our study, the addition of rapa-
mycin was employed to block mTOR signaling and
differentiate the effects of AA ratios from mTOR signal-
ing. A putative negative-feedback inhibition of Akt by
mTOR was ruled out because previous research with
mammary cells utilizing a complete AA mixture revealed
no change in phosphorylation status of Akt after the
addition of rapamycin [9].
Because the OPAA treatment stimulated gene expres-
sion of enzymes related to de novo FA synthesis
(ACACA, FASN) and desaturation (SCD), triacylglycerol
(TAG) synthesis (LPIN1), and transcription regulation of
lipid synthesis (SREBF1, INSIG1), relative to OPAARMC
the present data demonstrated that mTOR is, in fact, a
regulator of lipid metabolism in mammary cells. The
role of mTOR in lipogenesis has been previously demon-
strated in murine hepatic cells [22, 23]. In fact, mTOR
was essential for insulin-induced hepatic lipogenesis
through the IRS-P13K-Akt pathway [23]. The mechan-
ism proposed by these authors for mTOR regulation of
lipogenesis is related to Akt-mediated phosphorylation
of mTOR increasing gene expression of SREBF1 in an
S6K-independent manner [23]. The stimulation of
SREBF1 expression when OPAA was added to the
medium without rapamycin, relative to OPAARMC, is
further suggestive of this mechanism.
Evidence indicates that SREBF1 plays an important

































































































































Fig. 2 Expression of MIR21, MIR27AB, MIR34A, MIR103, MIR130A,
MIR378 and MIR448. Superscript letters denote significant differences
among treatments (P < 0.05). Symbols denote a tendency (P = 0.07)
for significant differences among treatments. OPAARMC = optimal
amino acid with rapamycin (control); OPAA = optimal amino acid;
LT2.1 = Lys:Thr at 2.1; LT1.3 = Lys:Thr at 1.3; LH3.0 = Lys:His at 3.05;
LV1.6 = Lys:Val at 1.62
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epithelial cells [24]. Ma and Corl [24] reported that the
expression of ACSS2, FABP3, SCD, and LPIN1 decreased
by blocking transcription of SREBF1 with small interfer-
ing RNA technology. The response was indicative of a
positive correlation among these genes. Therefore, the
up-regulation of SREBF1 with OPAA may have contrib-
uted to the greater expression of genes related to de
novo FA and TAG synthesis.
Regarding the pathway by which mTOR stimulates
SREBF1, Peterson et al. [25] demonstrated that
mTORC1 phosphorylates lipin (LPIN1) in a murine hep-
atic cell line, which prevents its nuclear entry and subse-
quent inhibition of SREBF1. However, lipin plays a dual
role in hepatic cells, both as transcriptional co-activator
and as an enzyme in TAG synthesis [26]. Therefore, the
LPIN1 gene expression measured in this experiment is
more likely reflective of its enzymatic role, which is in
agreement with the upregulation of the FA synthesis en-
zymes. Because we did not attempt to determine intra-
cellular location of lipin protein, we cannot infer directly
about its function as transcriptional co-activator.
Another pathway that links mTOR with lipogenic regu-
lation is through S6K-mediated phosphorylation of liver-
X-receptor-α (NR1H3), a transcriptional regulator that
senses oxysterols, dimerizes with retinoid-X-receptor-α
(RXRA) and activates transcription of SREBF1, FASN,
SCD and ACACA [27]. Liver-X-receptor-α (NR1H3) is a
potentially-important transcription regulator of milk fat
synthesis that enhances de novo FA synthesis in bovine
MEC treated with the NR1H3 agonist T0901317 [28].
Despite the fact that no effect of rapamycin was observed
on NR1H3, it is still possible that mTORC1 activation
stimulated phosphorylation of the NR1H3 product, liver-
X-receptor-α. However, the downregulation of RXRA
expression with OPAA relative to OPAARMC is a stron-
ger indication that NR1H3 was not involved in the ob-
served lipogenic up-regulation, because NR1H3 needs to
form heterodimers with RXRA to regulate the transcrip-
tion of lipogenic enzymes [29]. Therefore, despite evi-
dence in non-ruminant hepatocytes of an LXR-mediated
mTOR lipogenic effect, additional studies will have to be
performed to better understand the mechanisms whereby
NR1H3 may contribute to the regulation of lipogenic
genes in bovine mammary gland.
In the absence of up-regulation of NR1H3 with OPAA,
the increase in mRNA expression of genes related to de
novo synthesis (ACACA and FASN) and desaturation
(SCD) might have been controlled by other transcrip-
tional regulators such as SREBF1 and INSIG1. This idea
is supported by data from Oppi-Williams et al. [30], who
reported lower SCD mRNA expression in SREBF1-
knockdown Mac-T cells [30]. However, the higher ex-
pression of INSIG1, if extended to the protein level,
might have resulted in a lower activity of SREBF1, which
would have been retained in the ER via SCAP-INSIG1
binding [31], despite its concomitant higher expression.
This would suggest the involvement of other key tran-
scription regulators in lipid synthesis, as observed for
non-ruminants [32]. For instance, the increase in expres-
sion of PPARG in bovine mammary tissue during lactation
indicated that milk fat synthesis might be under partial
control by PPARγ [13]. The PPAR isotypes (α, δ, γ) are ac-
tivated to various extents by long-chain fatty acids (LCFA)
in MEC, hence, making them potential targets for fine-
tuning metabolism via nutrients [33]. Kadegowda et al.
[19] demonstrated that genes related to de novo FA syn-
thesis (ACACA, FASN), TAG synthesis (AGPAT6, DGAT1,
LPIN1), and transcriptional regulation of lipid synthesis
(SREBF1, INSIG1) were upregulated in Mac-T cells by
treatment with a PPARG agonist (rosiglitazone).
Despite the lack of effect of mTOR on PPARG, the up-
regulation of lipogenic genes in OPAA compared with
OPAARMC indicates that EAA could indirectly alter
PPARG, hence, play a role in de novo FA and TAG
synthesis regulation [33].
In a similar manner, Blanchard et al. [34] working with
adipocytes uncovered evidence of mTOR regulation of
PPARG transcriptional activity in the absence of changes
in PPARG mRNA expression. The authors suggested
that the regulatory mechanisms might involve covalent
and allosteric modulation of PPARG and/or its co-
regulators [34]. In fact, the PPARG co-regulators
PPARGC1A and LPIN1 are substantially up-regulated
during lactation in bovine mammary cells, indicating an
important role in milk fat synthesis [13]. In that context,
the upregulation of LPIN1 in the rapamycin-free
medium is noteworthy.
The up-regulation of PPARD was associated with
greater expression of genes related to de novo FA syn-
thesis (ACACA, FASN), desaturation (SCD), and intra-
cellular FA transport (FABP3), all of which agrees with a
positive correlation reported among these genes in a
previous Mac-T cell study [35]. Further research to de-
termine a role for PPARD in de novo FA synthesis will
have to be performed because correlations were weaker
compared with that for SREBF1 [35].
Although we did not include a treatment devoid of
EAA and insulin, the observed expression level of the
lipogenic genes (ACACA, FASN, SCD) in response to
OPAA provides some indication of EAA as regulators of
transcription in bovine mammary cells. The insulin ef-
fect alone or in combination with a mixture of EAA on
lipogenic gene expression (e.g. FASN, SREBF1) in cells
such as hepatocytes is clear [11, 36]. In fact, the potent
effect of EAA plus insulin in up-regulating FASN and
SREBF1 appears to require mTOR because incubating
EAA plus insulin plus RMC completely prevented the
up-regulation of lipogenic genes [36]. Data from
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hepatocyte incubations with Leu, Met, and Lys further
confirmed that the presence of insulin is essential for
up-regulation of FASN and other lipogenic genes [13].
Because lipogenesis is controlled differently in ruminants
than non-ruminants [37], e.g. ruminant mammary tissue
does not have an absolute requirement for insulin to
perform lipogenesis, the lipogenic role of insulin signal-
ing in the bovine mammary gland (via IRS1 and AKT1),
and that of mTOR, might be more biologically-
meaningful as lactation progresses [38], i.e. when sensi-
tivity of the mammary gland to insulin is greater. A
greater sensitivity of the mammary gland to insulin after
peak lactation (i.e. when the cow reaches positive energy
balance) would coincide with the greater expression of
genes associated with insulin signaling in mammary tis-
sue [38].
Regulation of mammary lipogenic genes by the specific
ratios of EAA
Lys to Thr ratios
Previous work with murine mammary cells revealed that
an increase in Thr has a negative effect on mTOR and
S6K1 phosphorylation status [9]. Conversely, Arriola-
Apelo et al. [7] observed stimulatory effects of Thr on
mTOR phosphorylation when incubated alone with
mammary tissue slices. However, Thr is antagonistic to
Ile and reduced the positive effect of the latter on phos-
phorylation status of mTOR and S6 [7]. The fact that
both LT2.1 and LT1.3 (rapamycin-free) up-regulated
ACSS2, FABP3, ACACA, FASN, SCD, LPIN1, INSIG1,
SREBF1, and PPARD relative to OPAARMC indicates
that a functional bovine mammary mTOR pathway is re-
quired for upregulation of lipogenic genes.
Lys to His ratio
Although LH3.0 resulted in up-regulation of several
lipogenic genes, the fact that expression of ACSS2,
FASN, SREBF1, and INSIG1 was different compared with
treatments like LT1.3 and LV1.6 also is indicative of
unique effects of His on lipogenic gene transcription.
These responses are indicative of a potentially novel and
important role in regulating lipogenic gene transcription.
Previous work with murine [9] mammary cells indicated
that His is a potential inhibitor of mTOR, but our data
and that from other groups [4–6] do not indicate a simi-
lar effect in bovine mammary cells. Although no direct
data linking His with lipogenic gene transcription exist,
at least in rat liver and muscle, it is clear that AA com-
position of dietary protein not only can modulate lipo-
genic enzyme activity but also gene transcription [39].
Lys to Val ratio
Among all treatments studied, the most significant ef-
fects on transcription compared with OAARMC were
detected with LV1.6 (Fig. 1), e.g. greatest expression of
ACSL1, SREBF1, RXRA, and NR1H3. In addition, it re-
sulted in the lowest expression of PPARG. These data
seem to indicate that lipogenic gene transcription is par-
ticularly sensitive to cellular availability of Val and that,
below a certain level, it could have a negative effect. The
fact that LV1.6 up-regulated ACSL1 compared with
other treatments is noteworthy because the expression
of this gene at the onset of lactation in bovine mammary
tissue is markedly up-regulated [13]. The down-
regulation of PPARG expression with LV1.6 could be
partly related with the up-regulation of SREBF1, N1HR3,
and RXRA, i.e. a compensatory mechanism to help
maintain lipogenic gene transcription.
Regulation of mammary miRNA by EAA
The process of milk fat synthesis in mammary epithelial
cells involves not only de novo synthesis but also TAG
synthesis and fat droplet formation, all of which are po-
tentially regulated by miRNA [40]. MicroRNA are short,
non-coding molecules that have an important role in
gene expression. Several studies have demonstrated that
miRNA silences target mRNA by degradation or transla-
tion repression [15]. However, miRNA can also function
to induce gene expression by targeting promoter se-
quences [41] or even increase protein translation by
binding to complementary promoter sequences [42]. Al-
though the biological functions of most miRNA are un-
known, it is estimated that >30 % of protein-coding
genes are regulated by miRNA [43].
The pattern of response of MIR27AB observed in this
study is in agreement with previous reports demonstrat-
ing a negative correlation among MIR27 and genes re-
lated to fatty acid and TAG synthesis in goat mammary
gland [44] and murine cells [14]. The mechanism re-
sponsible for such effect is through MIR27 directly tar-
geting the 3’ untranslated region (UTR) of PPARG
mRNA, decreasing its abundance [14], which does not
agree with our PPARG results. It was expected that
PPARG mRNA expression would be up-regulated be-
cause of the down-regulation of MIR27AB, but this was
not observed.
Another miRNA considered anti-adipogenic is
MIR130. MicroRNA 130 also targets PPARG, strongly
repressing its expression by targeting two functional
sites in the mRNA: the 3’ UTR and the coding region
[45]. A recent study reported abundant expression of
MIR130b in goat mammary gland tissue and revealed a
negative adipogenic effect potentially through inhibition
of PPARGC1A [46]. Similarly to what happens for
PPARG, MIR130b potently repressed PPARGC1A ex-
pression by targeting both the PPARGC1A mRNA cod-
ing region and 3’UTR [46]. However, the lower
expression of MIR130A in all rapamycin-free treatments
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does not agree with the decrease in PPARG expression.
It might be possible that MIR130A does not function in
the same manner as MIR130B.
The discrepancy between the response in expression
of PPARG and the two PPARG-targeting miRNA indi-
cates that regulation of both PPARG and other lipogenic
genes is complex, involves multiple regulators, as well as
post-transcription and post-translational regulation. In
addition, PPARG itself regulates transcription of many
miRNA. The lower expression of MIR27AB and
MIR130A with OPAA relative to OPAARMC is note-
worthy because it seems to indicate that mTOR some-
how might be involved in regulating their expression.
In contrast to MIR27AB and MIR130A, MIR21 in hu-
man cells has a pro-lipogenic effect [47]. More specifically,
MIR21 promotes an HBP1-mediated inhibition of p53 ex-
pression, which in turn, inhibits SREBF1 expression [47,
48]. This relationship was confirmed in the treatments
LT2.1, LT1.3, and LH3.0, in which both MIR21 and SREBF1
as well as most of the lipogenic genes were up-regulated.
Among all treatments, LV1.6 promoted the highest SREBF1
expression, while MIR21 expression was lower compared
with LT2.1, LT1.3 and LH3.0. The reason for these re-
sponses remains to be determined, as we are unaware of
any known regulatory effect of EAA on the HBP1-p53-
SREBP1c pathway [48]. Therefore, although without eluci-
dating mechanisms of action, our results indicate important
roles of MIR27AB, MIR130A and MIR21 in mammary
lipogenesis, as well as in the relationship between EAA and
lipid synthesis. Despite some of them having recognized
regulatory functions in lipogenesis (MIR103, MIR378,
MIR34A; [45], the other miRNA evaluated in this study
were not affected by the treatments.
Most studies evaluating the roles of miRNA in regula-
tion of lipid synthesis have been performed with murine
or human cell lines. However, a recent publication identi-
fied several miRNA that change in expression in the mam-
mary gland of cows after feeding a milk fat-depressing diet
(MFD) [49]. Besides revealing novel miRNA expressed in
bovine, that research revealed a total of 7 miRNA with a
strong differential expression during MFD. Six of them
(miR-199c, miR-199a-3p, miR-98, miR-378, miR-148b and
miR-21-5p) were up-regulated, while 1 (miR-200a) was
down-regulated. Therefore, our data add to the current
knowledgebase and emphasizes the importance of miRNA
in milk fat synthesis regulation in the context of EAA and
the mTOR pathway.
Conclusions
The observed up-regulation of lipogenic gene networks
and the changes in expression of key miRNA involved in
the control of lipogenic balance are indicative of a po-
tentially important role of EAA ratios and mTOR signal-
ing in the regulation of milk fat synthesis.
Additional file
Additional file 1: Table S1. GenBank accession number, hybridization
position, sequence, amplicon size of primers used1. (DOCX 18 kb)
Abbreviations
AA, amino acid; ACACA, Acetyl-coenzyme A carboxylase alpha; ACSL1,
Acyl-CoA synthetase long-chain family member 1; ACSS2, Acyl-CoA synthetase
short-chain family member 2; AGPAT6, 1-acylglycerol-3-phosphate
O-acyltransferase 6; DGAT1, diacylglycerol acyltransferase 1; EAA, essential
amino acids; EIF4E, eukaryotic translation initiation factor 4E; EIF4EBP1,
eukaryotic translation initiation factor 4E-binding protein 1; FA, fatty acid;
FABP3, fatty acid-binding protein, heart; FASN, fatty acid synthase;
GADPH, glyceraldehyde 3-phosphate dehydrogenase; INSIG1, insulin
induced gene 1; LCFA, long-chain fatty acids; LPIN1, lipin 1; Mac-T,
bovine mammary epithelial cells; MEC, mammary epithelial cells; MFD,
milk fat-depressing diet; MIR103, microRNA 103; MIR130a, microRNA
130a; MIR21, microRNA 21; MIR27ab, microRNA 27ab; MIR34a, microRNA
34a; MIR378, microRNA 378; MIR448, microRNA 448; miRNA, microRNA;
MTOR, mechanistic target of rapamycin (Ser/Thr kinase); mTORC1, mTOR
complex 1; NR1H3, liver X receptor α; PPARD, peroxisome proliferator-
activated receptor beta; PPARG, peroxisome proliferator-activated
receptor gamma; RHEB, ras homolog enriched in brain; RIN, RNA integrity;
RMC, rapamycin; RPS6KB1, ribosomal protein S6 kinase beta-1; RPS9, ribosomal
protein S9; RXRA, retinoid X receptor, alpha; SCD, stearoyl-CoA desaturase;
SREBF1, sterol regulatory element-binding transcription factor 1; TAG,
triacylglycerol; TSC1, tuberous sclerosis 1; UXT, ubiquitously expressed
prefoldin like chaperone
Acknowledgments
Gratitude is extended to China Scholarship Council (CSC) for awarding a
scholarship to S. S. Li to perform this study at the University of Illinois
(Urbana-Champaign).
Funding
J. X. Liu’s laboratory is recipient of funds from China MoST (Grant No.
2011CB100801). Experimental work was supported by Hatch funds allocated
to University of Illinois (ILLU-538-914; J.J. Loor). The funders had no role in
the design of the study and collection, analysis, and interpretation of data
and in writing of the manuscript.
Availability of data and materials
The datasets during and/or analyzed during the current study available from
the corresponding authors on reasonable request.
Author’s contributions
SSL, AH, and CBJ performed the experiment, performed analyses, and
analyzed data. SSL, MD, and JJL drafted the manuscript. JJL, AH, and JXL
conceived the experiment and proofread the manuscript. All authors
participated in data interpretation. All authors approved the final version of
the manuscript.
Author’s information
S. S. Li is PhD degree candidate at Institute of Dairy Science, College of
Animal Sciences, Zhejiang University, Hangzhou 310058, China. A. Hosseini is
post-doctoral fellow in the Department of Animal Sciences, University of
Illinois, Urbana, IL, 61801, USA. M. A. C. Danes is Assistant Professor in the
Department of Animal Science, University of Lavras, Lavras, MG, Brazil. C. B.
Jacometo is post-doctoral fellow at NUPEEC, Departamento de Clínicas
Veterinária, Programa de Pós-Graduação em Biotecnologia, Universidade
Federal de Pelotas, 96010–900 Pelotas, RS, Brazil. J. X. Liu is Professor at
Institute of Dairy Science, College of Animal Sciences, Zhejiang University,
Hangzhou 310058, China. J. J. Loor is Associate Professor in the Department
of Animal Sciences, University of Illinois, Urbana, IL, 61801, USA.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Li et al. Journal of Animal Science and Biotechnology  (2016) 7:44 Page 9 of 11
Ethics approval and consent to participate
Not applicable.
Author details
1Institute of Dairy Science, College of Animal Sciences, Zhejiang University,
Yuhangtang Road 866, Hangzhou 310058, People’s Republic of China.
2Department of Animal Sciences, Mammalian NutriPhysioGenomics,
University of Illinois, 1207 West Gregory Drive, Urbana, IL 61801, USA.
3Department of Animal Science, University of Lavras, Lavras, MG 37200-000,
Brazil. 4NUPEEC, Departamento de Clínicas Veterinária, Programa de
Pós-Graduação em Biotecnologia, Universidade Federal de Pelotas,
96010-900 Pelotas, RS, Brazil.
Received: 23 December 2015 Accepted: 19 July 2016
References
1. Haque MN, Guinard-Flament J, Lamberton P, Mustiere C, Lemosquet S.
Changes in mammary metabolism in response to the provision of an ideal
amino acid profile at 2 levels of metabolizable protein supply in dairy cows:
consequences on efficiency. J Dairy Sci. 2012;98:3951–68.
2. Rulquin H, Raggio G, Lapierre H, Lemosquet S. Relationship between
intestinal supply of essential amino acids and their mammary metabolism
in the lactating dairy cow. In: Energy and Protein Metabolism and Nutrition.
EAAP Publ. No. 124. Wageningen, the Netherlands: Wageningen Academic
Publishers; 2007. p. 587–8.
3. Lapierre H, Pacheco D, Berthiaume R, Ouellet DR, Schwab CG, Dubreuil P,
et al. What is the true supply of amino acids for a dairy cow? J Dairy Sci.
2006;89 Suppl 1:E1–14.
4. Appuhamy JA, Bell AL, Nayananjalie WA, Escobar J, Hanigan MD. Essential
amino acids regulate both initiation and elongation of mRNA translation
independent of insulin in MAC-T cells and bovine mammary tissue slices.
J Nutr. 2011;141:1209–15.
5. Appuhamy JA, Knoebel NA, Nayananjalie WA, Escobar J, Hanigan MD.
Isoleucine and leucine independently regulate mTOR signaling and protein
synthesis in MAC-T cells and bovine mammary tissue slices. J Nutr.
2012;142:484–91.
6. Appuhamy JA, Nayananjalie WA, England EM, Gerrad DE, Akers RM, Hanigan
MD. Effects of AMP-activated protein kinase (AMPK) signaling and essential
amino acids on mammalian target of rapamycin (mTOR) signaling and
protein synthesis rates in mammary cells. J Dairy Sci. 2014;97:419–29.
7. Arriola Apelo SI, Singer LM, Lin XY, McGilliard ML, St-Pierre NR, Hanigan MD.
Isoleucine, leucine, methionine, and threonine effects on mammalian target
of rapamycin signaling in mammary tissue. J Dairy Sci. 2014;97:1047–56.
8. Castro JJ, Apelo SI, Appuhamy JA, Hanigan MD. Development of a model
describing regulation of casein synthesis by the mammalian target of
rapamycin (mTOR) signaling pathway in response to insulin, amino acids,
and acetate. J Dairy Sci 2016; doi: 10.3168/jds.2015-10591. [Epub ahead of
print]
9. Prizant RL, Barash I. Negative effects of the amino acids Lys, His, and Thr on
S6K1 phosphorylation in mammary epithelial cells. J Cell Biochem.
2008;105:1038–47.
10. Porstmann T, Santos CR, Griffiths B, Cully M, Wu M, Leevers S, et al. SREBP
activity is regulated by mTORC1 and contributes to Akt-dependent cell
growth. Cell Metab. 2008;8:224–36.
11. Lansard M, Panserat S, Plagnes-Juan E, Dias K, Seiliez I, Skiba-Cassy S.
L-leucine, L-methionine, and L-lysine are involved in the regulation of
intermediary metabolism-related gene expression in rainbow trout
hepatocytes. J Nutr. 2011;141:75–80.
12. Krause U, Bertrand L, Maisin L, Rosa M, Hue L. Signalling pathways and
combinatory effects of insulin and amino acids in isolated rat hepatocytes.
Eur J Biochem. 2002;269:3742–50.
13. Bionaz M, Loor JJ. Gene networks driving bovine milk fat synthesis during
the lactation cycle. BMC Genomics. 2008;9:366.
14. Karbiener M, Fischer C, Nowitsch S, Opriessnig P, Papak C, Ailhaud G, et al.
microRNA miR-27b impairs human adipocyte differentiation and targets
PPARgamma. Biochem Biophys Res Commun. 2009;390:247–51.
15. Romao JM, Jin W, Dodson MV, Hausman GJ, Moore SS, Guan LL. MicroRNA
regulation in mammalian adipogenesis. Exp Biol Med (Maywood).
2011;236:997–1004.
16. John E, Wienecke-Baldacchino A, Liivrand M, Heinäniemi M, Carlberg C,
Sinkkonen L. Dataset integration identifies transcriptional regulation of
microRNA genes by PPARγ in differentiating mouse 3 T3-L1 adipocytes.
Nucleic Acids Res. 2012;40:4446–60.
17. Wu H, Ng R, Chen X, Steer CJ, Song G. MicroRNA-21 is a potential link between
non-alcoholic fatty liver disease and hepatocellular carcinoma via modulation
of the HBP1-p53-Srebp1c pathway. Gut. 2015. doi: 10.1136/gutjnl-2014-308430.
18. Reue K, Zhang P. The lipin protein family: dual roles in lipid biosynthesis
and gene expression. FEBS Lett. 2008;582(1):90–6.
19. Grønning-Wang LM, Bindesbøll C, Nebb HI. The Role of Liver X Receptor in
Hepatic de novo Lipogenesis and Cross-Talk with Insulin and Glucose
Signaling, Lipid Metabolism, Prof. Rodrigo Valenzuela Baez (Ed.), ISBN:
978-953-51-0944-0, InTech, 2013 doi: 10.5772/51357.
20. Kadegowda AK, Bionaz M, Piperova LS, Erdman RA, Loor JJ. Peroxisome
proliferator-activated receptor-gamma activation and long-chain fatty acids
alter lipogenic gene networks in bovine mammary epithelial cells to various
extents. J Dairy Sci. 2009;92:4276–89.
21. Lee C, Hristov AN, Cassidy TW, Heyler KS, Lapierre H, Varga GA, et al.
Rumen-protected lysine, methionine, and histidine increase milk protein
yield in dairy cows fed a metabolizable protein-deficient diet. J Dairy Sci.
2012;95:6042–56.
22. Haque MN, Rulquin H, Lemosquet S. Milk protein responses in dairy cows to
changes in postruminal supplies of arginine, isoleucine, and valine. J Dairy
Sci. 2013;96:420–30.
23. Bionaz M, Loor JJ. Identification of reference genes for quantitative real-time
PCR in the bovine mammary gland during the lactation cycle. Physiol
Genomics. 2007;29:312–9.
24. Hwahng SH, Ki SH, Bae EJ, Kim HE, Kim SG. Role of adenosine
monophosphate-activated protein kinase-p70 ribosomal S6 kinase-1
pathway in repression of liver X receptor-alpha-dependent lipogenic gene
induction and hepatic steatosis by a novel class of dithiolethiones.
Hepatology. 2009;49:1913–25.
25. Li S, Brown MS, Goldstein JL. Bifurcation of insulin signaling pathway in rat
liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of
gluconeogenesis. Proc Natl Acad Sci U S A. 2010;107:3441–6.
26. Ma L, Corl BA. Transcriptional regulation of lipid synthesis in bovine
mammary epithelial cells by sterol regulatory element binding protein-1.
J Dairy Sci. 2012;95:3743–55.
27. Peterson TR, Sengupta SS, Harris TE, Carmack AE, Kang SA, Balderas E, et al. mTOR
complex 1 regulates lipin 1 localization to control the SREBP pathway. Cell. 2011;
146:408–20.
28. McFadden JW, Corl BA. Activation of liver X receptor (LXR) enhances de
novo fatty acid synthesis in bovine mammary epithelial cells. J Dairy Sci.
2010;93:4651–8.
29. Willy PJ, Umesono K, Ong ES, Evans RM, Heyman RA, Mangelsdorf DJ. LXR, a
nuclear receptor that defines a distinct retinoid response pathway. Genes
Dev. 1995;9:1033–45.
30. Oppi-Williams C, Suagee JK, Corl BA. Regulation of lipid synthesis by liver X
receptor alpha and sterol regulatory element-binding protein 1 in
mammary epithelial cells. J Dairy Sci. 2013;96:112–21.
31. Espenshade PJ, Hughes AL. Regulation of Sterol Synthesis in Eukaryotes.
Annu Rev Genet. 2007;41:401–27.
32. Pegorier JP, Le May C, Girard J. Control of gene expression by fatty acids.
J Nutr. 2004;134:2444S–9.
33. Bionaz M, Chen S, Khan MJ, Loor JJ. Functional role of PPARs in ruminants:
potential targets for fine-tuning metabolism during growth and lactation.
PPAR Res 2013:684159. doi: 10.1155/2013/684159
34. Blanchard PG, Festuccia WT, Houde VP, St-Pierre P, Brûlé S, Turcotte V, et al.
Major involvement of mTOR in the PPARγ-induced stimulation of adipose
tissue lipid uptake and fat accretion. J Lipid Res. 2012;53:1117–25.
35. Jacobs AA, Dijkstra J, Liesman JS, Vandehaar MJ, Lock AL, van Vuuren AM,
et al. Effects of short- and long-chain fatty acids on the expression of
stearoyl-CoA desaturase and other lipogenic genes in bovine mammary
epithelial cells. Animal. 2013;7:1508–16.
36. Lansard M, Panserat S, Plagnes-Juan E, Seiliez I, Skiba-Cassy S.
Integration of insulin and amino acid signals that regulate hepatic
metabolism-related gene expression in rainbow trout: role of TOR.
Amino Acids. 2010;39:801–10.
37. Bergen WG, Mersmann HJ. Comparative aspects of lipid metabolism:
impact on contemporary research and use of animal models. J Nutr.
2005;135:2499–502.
Li et al. Journal of Animal Science and Biotechnology  (2016) 7:44 Page 10 of 11
38. Bionaz M, Loor JJ. Gene networks driving bovine mammary protein
synthesis during the lactation cycle. Bioinform Biol Insights. 2011;5:83–98.
39. Morifuji M, Sakai K, Sanbongi C, Sugiura K. Dietary whey protein
downregulates fatty acid synthesis in the liver, but upregulates it in skeletal
muscle of exercise-trained rats. Nutrition. 2005;21:1052–8.
40. Lin X, Luo J, Zhang L, Wang W, Gou D. MiR-103 controls milk fat
accumulation in goat (Capra hircus) mammary gland during lactation. PLoS
One. 2013;8, e79258.
41. Place RF, Li L-C, Pookot D, Noonan EJ, Dahiya R. MicroRNA-373 induces
expression of genes with complementary promoter sequences. Proc Natl
Acad Sci U S A. 2008;105:1608–13.
42. Vasudevan S, Tong Y, Steitz JA. Switching from repression to activation:
microRNAs can up-regulate translation. Science. 2007;318:1931–4.
43. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by
adenosines, indicates that thousands of human genes are microRNA
targets. Cell. 2005;120:15–20.
44. Lin XZ, Luo J, Zhang LP, Wang W, Shi HB, Zhu JJ. miR-27a suppresses
triglyceride accumulation and affects gene mRNA expression associated
with fat metabolism in dairy goat mammary gland epithelial cells. Gene.
2013;521:15–23.
45. Lee EK, Lee MJ, Abdelmohsen K, Kim W, Kim MM, Srikantan S, et al.
2011. miR-130 suppresses adipogenesis by inhibiting peroxisome
proliferator-activated receptor gamma expression. Mol Cell Biol. 2011;31:
626–38.
46. Chen Z, Luo J, Ma L, Wang H, Cao W, Xu H, et al. MiR130b- Regulation of
PPARγ coactivator-1α suppresses fat metabolism in goat mammary
epithelial cells. PLoS One. 2015;10, e0142809.
47. Wu H, Ng R, Chen X, Steer CJ, Song G. MicroRNA-21 is a potential link
between non-alcoholic fatty liver disease and hepatocellular carcinoma via
modulation of the HBP1-p53-Srebp1c pathway. Gut 2015; doi: 10.1136/
gutjnl-2014-308430.
48. Wang X, Zhao X, Gao X, Mei Y, Wu M. A new role of p53 in regulating lipid
metabolism. J Mol Cell Biol. 2013;5:147–1450.
49. Li R, Beaudoin F, Ammah AA, Bissonnette N, Benchaar C, Zhao X, et al.
Deep sequencing shows microRNA involvement in bovine mammary gland
adaptation to diets supplemented with linseed oil or safflower oil. BMC
Genomics. 2015;16:884.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Li et al. Journal of Animal Science and Biotechnology  (2016) 7:44 Page 11 of 11
